5th Jan 2021 21:15
Destiny Pharma PLC - clinical stage biotechnology company based in Brighton - Completes recruitment of patients undergoing open heart surgery in the US and Europe for its XF-73 phase 2b clinical study. The study will assess the microbiological effect of XF-73 nasal gel on Staphylococcus aureus nasal carriage in patients scheduled for open heart surgery.
"We previously reported excellent interim safety data in mid-2020 and are now looking forward to announcing the full results of this study and planning the Phase 3 clinical programme," says Chief Executive Neil Clark.
Current stock price: 75.20 pence
Year-to-date change: up 9.8%
By Ife Taiwo; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
DEST.L